Search research articles
Contact Us
Filters
Showing results (91-100 of 118) with videos related to
Page
of 12
Sort By:
Nature Genetics
|
September 8, 2015
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, et al.
Plos Medicine
|
July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma
Jeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Hepatology Communications
|
August 5, 2024
Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy
Paul R Burchard, Luis I Ruffolo, Nicholas A Ullman, et al.
Cancer Cell
|
January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cancer Discovery
|
December 5, 2024
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches
Yi Xu, Xianlu L Peng, Michael P East, et al.
NPJ Precision Oncology
|
April 17, 2018
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule
Małgorzata A Witek, Rachel D Aufforth, Hong Wang, et al.
The Journal of Clinical Investigation
|
August 5, 2020
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
Honglin Jiang, Robert J Torphy, Katja Steiger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 28, 2020
Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer
Divya Thomas, Satish Sagar, Xiang Liu, et al.
Nature Communications
|
November 2, 2021
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, et al.
Nature Communications
|
June 9, 2017
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
Sean T Bailey, Aleisha M Smith, Jordan Kardos, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 118) with videos related to
Sort By:
Page
of 12
Nature Genetics
|
September 8, 2015
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, et al.
Plos Medicine
|
July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma
Jeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Hepatology Communications
|
August 5, 2024
Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy
Paul R Burchard, Luis I Ruffolo, Nicholas A Ullman, et al.
Cancer Cell
|
January 4, 2016
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K Hayes, Nicole F Neel, Chaoxin Hu, et al.
Cancer Discovery
|
December 5, 2024
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches
Yi Xu, Xianlu L Peng, Michael P East, et al.
NPJ Precision Oncology
|
April 17, 2018
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule
Małgorzata A Witek, Rachel D Aufforth, Hong Wang, et al.
The Journal of Clinical Investigation
|
August 5, 2020
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
Honglin Jiang, Robert J Torphy, Katja Steiger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 28, 2020
Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer
Divya Thomas, Satish Sagar, Xiang Liu, et al.
Nature Communications
|
November 2, 2021
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, et al.
Nature Communications
|
June 9, 2017
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
Sean T Bailey, Aleisha M Smith, Jordan Kardos, et al.
Page
of 12